AS1411 aptamer can function as a recognition probe to detect the cell surface nucleolin
overexpressed in cancer cells, however, little is known about their binding process. This …

We have designed AS1411-N6, a derivative of the nucleolin (NCL)-binding aptamer
AS1411, by adding six nucleotides to the 5′-end that are complementary to nucleotides at …

Targeted therapy is highly desirable, as it allows for selective cytotoxicity on diseased cells
without off-target side effects. Nucleolin is a remarkable target for cancer therapy given its …

Aptamers can be chemically modified to enhance nuclease resistance and increase target
affinity. In this study, we performed chemical modification of 2′-deoxyinosine in AS1411, an …

G-rich aptamers such as AS1411 are small oligonucleotides that present several benefits
comparatively to monoclonal antibodies, since they are easier to manufacture and store …

Background: It has been expected that AS1411 aptamer could work against the cancer cells.
Although the general information is available, there is still lack of details for the purpose …

Chemically modified nucleotides have been developed and applied into SELEX procedure
to find a novel type of aptamers to fit with targets of interest. In this study, we directly …

Nucleolin or C23, is one of the most abundant non-ribosomal phosphoproteins of nucleolus.
However, in several cancers, nucleolin is highly expressed both intracellularly and on the …

Aptamers are promising therapeutic and diagnostic agents for various diseases due to their
high affinity and specificity against target proteins. Structural determination in combination …

AS1411 is a nucleolin-binding aptamer which attracted great interest as active targeting
ligand for the selective delivery of therapeutic agents to tumour cells. In this work we …